Venlafaxine pharmacogenetics: a comprehensive review

Area of Science:

• Pharmacogenetics
• Neuroscience
• Clinical Pharmacology

Background:

• Antidepressant response is significantly influenced by genetic factors, estimated between 42-50%.
• Venlafaxine (VEN) is a widely prescribed antidepressant, making its pharmacogenetics a critical area of study.
• Current understanding of VEN pharmacogenetics is limited, with a lack of established guidelines for genetic testing.

Purpose of the Study:

• To review existing literature on the pharmacogenetics of venlafaxine (VEN).
• To identify genetic polymorphisms that may predict VEN efficacy and tolerance.
• To highlight the need for further research to guide personalized pharmacotherapy.

Main Methods:

• Systematic review of studies investigating the pharmacogenetics of venlafaxine (VEN).
• Analysis of genetic polymorphisms and their association with VEN treatment outcomes.
• Evaluation of current guidelines and evidence for pharmacogenetic testing.

Main Results:

• Few genetic polymorphisms have been identified as reliable predictors of VEN efficacy or tolerance.
• Existing research presents contradictory findings, necessitating replication and further investigation.
• There is a significant gap in established guidelines for pharmacogenetic testing for VEN.

Conclusions:

• Further pharmacogenetic studies on VEN are essential to validate existing findings and resolve discrepancies.
• Personalized pharmacotherapy, informed by pharmacogenetics, is crucial for optimizing patient treatment outcomes.
• Integrating pharmacogenetic insights into VEN prescribing can enhance treatment efficacy and safety.